Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 18, 2011 - Issue 4
194
Views
24
CrossRef citations to date
0
Altmetric
Original Article

Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis

, , , , , , , , , , , , & show all
Pages 216-221 | Received 17 Sep 2011, Accepted 22 Sep 2011, Published online: 09 Nov 2011
 

Abstract

Background: Cardiac biomarkers play a major role in the identification of patients at risk of early death in AL amyloidosis, and a staging system based on amino-terminal pro-natriuretic peptide type-B (NT-proBNP) and troponins (cTn) is used for prognostic stratification. Adrenomedullin is produced by several tissues including the heart, and portends a poor prognosis in heart diseases. We investigated the ability of midregional proadrenomedullin (MR-proADM) to predict early death in AL amyloidosis. Methods: One-hundred and thirty consecutive patients with newly-diagnosed AL amyloidosis were prospectively enrolled. The impact on survival of NT-proBNP, cTnI and MR-proADM was evaluated. Results: The concentration of MR-proADM correlated with systolic and diastolic function, but did not reflect the amount of amyloid deposited in the heart. Moreover, MR-proADM was associated with non-cardiac markers of advanced disease. The staging system based on NT-proBNP and cTnI identified high-risk subjects, but could not discriminate good-risk and intermediate-risk patients. Conversely, a staging system based on MR-proADM and cTnI identified 3 groups with significantly different survivals. Conclusions: Midregional-proADM is a powerful prognostic marker in AL amyloidosis, which may not only reflect cardiac dysfunction but also widespread systemic disease, and can be combined with cTn for detecting patients at risk of early death.

Acknowledgments

The Authors are grateful to Dr. Leda Roggeri for data management and thank B.R.A.H.M.S. Biomarkers for providing the reagents for measuring midregionalproadrenomedullin.

Declaration of interest: The authors have no conflict of interest to disclose. This work was supported by grants from the, Ministry of Health (Ricerca Finalizzata Malattie Rare), “Istituto Superiore di Sanità” (526D/63); Ministry of Research and University (2007AESFX2_003); and “Associazione Italiana per la Ricerca sul Cancro” Program “Harnessing tumor cell/microenvironment cross talk to treat mature B cell tumors”.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.